|
Renovo is a biopharmaceutical product company and is the world leader in the development of drugs to reduce scarring. Scarring can result from acute injury in, or surgery to the skin, nerves, tendons and ligaments, eyes, internal organs and blood vessels. These are high value markets of significant unmet medical need.
Our pipeline is extensive and includes one drug that has recently initiated phase 3 clinical development, three drugs in phase 2 clinical development and numerous pre-clinical candidates.
There is an estimated multi-billion dollar global market for anti-scarring drugs, and Renovo aims to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need.
In June 2007 Renovo announced that it had signed an exclusive licensing agreement with Shire plc to develop and commercialise Juvista, its lead product for the reduction of scarring. As part of this agreement Renovo retained all rights to Juvista in the European Union.
|
|
NEWS
|
Latest Presentations
|
EVENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHARE PRICE
|
|
|
|
|
|
|
|
Data supplied by AXL Performance
Solutions - http://www.axl.co.uk |
|
|
|
|
|
|
|
|
|
